Omer has led our clinical group, overseeing planning and execution of clinical development programs since August 2017. Omer joined Alector from Allakos, a biotechnology company focusing on developing therapeutic antibodies targeting allergic and inflammatory diseases, where he was the Vice President of Clinical Operations and a member of the executive team from 2015 to 2017. He led the progression of the leading antibody programs from first in human to proof of concept in patients. Prior to Allakos, Omer spent more than 5 years at Genentech from 2010 to 2015, where most recently as the Program Group Lead in the Early Clinical Development gRED, he was responsible for oversight of clinical trials in multiple programs across immunology, neuroscience and infectious diseases. Earlier in his career, Omer worked at INC Research, Eli Lilly, and MDS Pharma Services in leadership roles in clinical study management. Omer completed his BSc in Biology from the University of Western Ontario in Canada, and completed his MSc in biotechnology at Johns Hopkins University.